Novacyt S.A. (NVYTF)
- Previous Close
0.5380 - Open
0.5000 - Bid 0.6073 x 100000
- Ask 0.6494 x 636700
- Day's Range
0.5000 - 0.5000 - 52 Week Range
0.5000 - 1.2500 - Volume
91 - Avg. Volume
1 - Market Cap (intraday)
44.734M - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7400 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.
www.novacyt.comRecent News: NVYTF
View MorePerformance Overview: NVYTF
Trailing total returns as of 6/10/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVYTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVYTF
View MoreValuation Measures
Market Cap
44.55M
Enterprise Value
19.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.43
Price/Book (mrq)
0.59
Enterprise Value/Revenue
0.73
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-212.72%
Return on Assets (ttm)
-10.19%
Return on Equity (ttm)
-57.28%
Revenue (ttm)
19.63M
Net Income Avi to Common (ttm)
-38.7M
Diluted EPS (ttm)
-0.7400
Balance Sheet and Cash Flow
Total Cash (mrq)
30.64M
Total Debt/Equity (mrq)
24.81%
Levered Free Cash Flow (ttm)
-13.66M